Global Diabetic Neuropathy

Diabetic Neuropathy Comprehensive Study by Type (Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy), Application (Hospitals, Clinics, Retail Pharmacy, Online Pharmacy), Drug Type (Analgesic (Topical, Opoid, NSAIDs), Antidepressants (TCAs, SNRIs, SSRIs), Anticonvulsant Drugs (Gabapentin, Pregabalin, Topiramate)), Therapy (Radiotherapy (Transcutaneous Electrical Nerve Stimulation (TENS)), Physiotherapy) Players and Region - Global Market Outlook to 2028

Diabetic Neuropathy Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
An estimated 50% of the diabetic population suffers from diabetic neuropathy across the globe. Further, as per the Center For Disease Control estimates, 6-7 people per 1000 diabetic population suffer from diabetic neuropathy in the United States. Increase in prevalence of diabetes due to the sedentary lifestyle, the rise in obese population due to improper diet, and growth in awareness regarding diagnosis & treatment of diabetes. These factors are propelling the growth of the market. Diabetic neuropathy is a nerve-damaging disorder which is associated with diabetes mellitus. Patients who suffer from diabetes since a long time are more prone to nerve damages throughout the body, as the symptoms of diabetic neuropathies cannot be diagnosed at an earlier stage. Although there is no cure for diabetic neuropathy, it can be suppressed or prevented using various treatment modalities.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledPfizer Inc. (United States), Janssen Pharmaceuticals, Inc. (Belgium), Eli Lilly and Company (India), Teva Pharmaceutical Industries (United States), Cephalon, Inc. (United States), MEDA Pharma GmbH & Co. KG (Germany), GlaxoSmithKline plc. (United Kingdom) and NeuroMetrix, Inc (United States)


This growth is primarily driven by The increasing prevalence of diabetes cases & Rising aging population, Advancement in healthcare expenditure for diabetes, Growing awareness about diabetes and related nerve complications and Rise in R&D activities in drug discovery and development.

Globally, a noticeable market trend is evident Increasing Number of Mergers and Acquisitions by the Market Players The Diseases & Therapeutic Areas sector in the North America region has been increasing at a sustainable rate, and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Pfizer Inc. (United States), Janssen Pharmaceuticals, Inc. (Belgium), Eli Lilly and Company (India), Teva Pharmaceutical Industries (United States), Cephalon, Inc. (United States), MEDA Pharma GmbH & Co. KG (Germany), GlaxoSmithKline plc. (United Kingdom) and NeuroMetrix, Inc (United States), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. The market is consolidated in nature with major pharmaceutical players accounting for major market share. As the majority of the current breed of drugs undergo patent expiration, the generic drugs will enter the market and the key competitors would have to introduce innovative products into the market to stay competitive. For instance, In February 2018, Daiichi Sankyo Company, Limited announces the marketing application of the pregabalin, for peripheral neuropathic pain (PNP) 2 in Japan. This application is based on phase 3 clinical trial in patients with diabetic peripheral neuropathic pain (DPNP)3 and a phase 3 clinical trial in patients with postherpetic neuralgia (PHN)*4 carried out in Asia, including Japan (primary endpoints were achieved in both trials).

Key Developments in the Market:
In February 2019,Teva Pharmaceutical Industries Ltd., announced the launch of a generic version of Sabril®1 (vigabatrin) tablets, 500 mg in the US, the first generic version of Sabril® (vigabatrin) tablets to enter the US market.
In Aug. 2023 Nevro Corp. , a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the publication of 24-month data from the SENZA Painful Diabetic Neuropathy (PDN) Randomized Controlled Trial (RCT), the largest RCT to evaluate spinal cord stimulation (SCS) to treat PDN, in Diabetes Research and Clinical Practice

Influencing Trend:
Increasing Number of Mergers and Acquisitions by the Market Players and Rapid Product Launches & Rise in the Number of Collaborations and Partnerships For The treatment of Diabetes neuropathy.

Market Growth Drivers:
The increasing prevalence of diabetes cases & Rising aging population, Advancement in healthcare expenditure for diabetes, Growing awareness about diabetes and related nerve complications and Rise in R&D activities in drug discovery and development

Challenges:
The strict regulatory scenario for drug approval in developed countries has been a challenge for the diabetic neuropathy market.

Restraints:
High Cost of Treatment for Diabetic Neuropathy and Side Effects associated with the Drugs may hamper the Market.

Opportunities:
Rising R&D Activities for Drug Discovery and Development & Increasing Government Supports in the form of funding Are Providing an Opportunity for the Market.

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Diabetic Neuropathy Market
- Analysis about New Entrants in Diabetic Neuropathy Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Diabetic Neuropathy Study Sheds Light on
— The Diabetic Neuropathy Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Diabetic Neuropathy industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Diabetic Neuropathy industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Peripheral Neuropathy
  • Autonomic Neuropathy
  • Proximal Neuropathy
  • Focal Neuropathy
By Application
  • Hospitals
  • Clinics
  • Retail Pharmacy
  • Online Pharmacy
By Drug Type
  • Analgesic (Topical, Opoid, NSAIDs)
  • Antidepressants (TCAs, SNRIs, SSRIs)
  • Anticonvulsant Drugs (Gabapentin, Pregabalin, Topiramate)

By Therapy
  • Radiotherapy (Transcutaneous Electrical Nerve Stimulation (TENS))
  • Physiotherapy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The increasing prevalence of diabetes cases & Rising aging population
      • 3.2.2. Advancement in healthcare expenditure for diabetes
      • 3.2.3. Growing awareness about diabetes and related nerve complications
      • 3.2.4. Rise in R&D activities in drug discovery and development
    • 3.3. Market Challenges
      • 3.3.1. The strict regulatory scenario for drug approval in developed countries has been a challenge for the diabetic neuropathy market.
    • 3.4. Market Trends
      • 3.4.1. Increasing Number of Mergers and Acquisitions by the Market Players
      • 3.4.2. Rapid Product Launches & Rise in the Number of Collaborations and Partnerships For The treatment of Diabetes neuropathy.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Diabetic Neuropathy, by Type, Application, Drug Type, Therapy and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Diabetic Neuropathy (Value)
      • 5.2.1. Global Diabetic Neuropathy by: Type (Value)
        • 5.2.1.1. Peripheral Neuropathy
        • 5.2.1.2. Autonomic Neuropathy
        • 5.2.1.3. Proximal Neuropathy
        • 5.2.1.4. Focal Neuropathy
      • 5.2.2. Global Diabetic Neuropathy by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Retail Pharmacy
        • 5.2.2.4. Online Pharmacy
      • 5.2.3. Global Diabetic Neuropathy by: Drug Type (Value)
        • 5.2.3.1. Analgesic (Topical, Opoid, NSAIDs)
        • 5.2.3.2. Antidepressants (TCAs, SNRIs, SSRIs)
        • 5.2.3.3. Anticonvulsant Drugs (Gabapentin, Pregabalin, Topiramate)
      • 5.2.4. Global Diabetic Neuropathy by: Therapy (Value)
        • 5.2.4.1. Radiotherapy (Transcutaneous Electrical Nerve Stimulation (TENS))
        • 5.2.4.2. Physiotherapy
      • 5.2.5. Global Diabetic Neuropathy Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Diabetic Neuropathy (Price)
      • 5.3.1. Global Diabetic Neuropathy by: Type (Price)
  • 6. Diabetic Neuropathy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Janssen Pharmaceuticals, Inc. (Belgium)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Eli Lilly and Company (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Teva Pharmaceutical Industries (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Cephalon, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. MEDA Pharma GmbH & Co. KG (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. GlaxoSmithKline plc. (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. NeuroMetrix, Inc (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Diabetic Neuropathy Sale, by Type, Application, Drug Type, Therapy and Region (value and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Diabetic Neuropathy (Value)
      • 7.2.1. Global Diabetic Neuropathy by: Type (Value)
        • 7.2.1.1. Peripheral Neuropathy
        • 7.2.1.2. Autonomic Neuropathy
        • 7.2.1.3. Proximal Neuropathy
        • 7.2.1.4. Focal Neuropathy
      • 7.2.2. Global Diabetic Neuropathy by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Retail Pharmacy
        • 7.2.2.4. Online Pharmacy
      • 7.2.3. Global Diabetic Neuropathy by: Drug Type (Value)
        • 7.2.3.1. Analgesic (Topical, Opoid, NSAIDs)
        • 7.2.3.2. Antidepressants (TCAs, SNRIs, SSRIs)
        • 7.2.3.3. Anticonvulsant Drugs (Gabapentin, Pregabalin, Topiramate)
      • 7.2.4. Global Diabetic Neuropathy by: Therapy (Value)
        • 7.2.4.1. Radiotherapy (Transcutaneous Electrical Nerve Stimulation (TENS))
        • 7.2.4.2. Physiotherapy
      • 7.2.5. Global Diabetic Neuropathy Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Diabetic Neuropathy (Price)
      • 7.3.1. Global Diabetic Neuropathy by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Diabetic Neuropathy: by Type(USD Million)
  • Table 2. Diabetic Neuropathy Peripheral Neuropathy , by Region USD Million (2017-2022)
  • Table 3. Diabetic Neuropathy Autonomic Neuropathy , by Region USD Million (2017-2022)
  • Table 4. Diabetic Neuropathy Proximal Neuropathy , by Region USD Million (2017-2022)
  • Table 5. Diabetic Neuropathy Focal Neuropathy , by Region USD Million (2017-2022)
  • Table 6. Diabetic Neuropathy: by Application(USD Million)
  • Table 7. Diabetic Neuropathy Hospitals , by Region USD Million (2017-2022)
  • Table 8. Diabetic Neuropathy Clinics , by Region USD Million (2017-2022)
  • Table 9. Diabetic Neuropathy Retail Pharmacy , by Region USD Million (2017-2022)
  • Table 10. Diabetic Neuropathy Online Pharmacy , by Region USD Million (2017-2022)
  • Table 11. Diabetic Neuropathy: by Drug Type(USD Million)
  • Table 12. Diabetic Neuropathy Analgesic (Topical, Opoid, NSAIDs) , by Region USD Million (2017-2022)
  • Table 13. Diabetic Neuropathy Antidepressants (TCAs, SNRIs, SSRIs) , by Region USD Million (2017-2022)
  • Table 14. Diabetic Neuropathy Anticonvulsant Drugs (Gabapentin, Pregabalin, Topiramate) , by Region USD Million (2017-2022)
  • Table 15. Diabetic Neuropathy: by Therapy(USD Million)
  • Table 16. Diabetic Neuropathy Radiotherapy (Transcutaneous Electrical Nerve Stimulation (TENS)) , by Region USD Million (2017-2022)
  • Table 17. Diabetic Neuropathy Physiotherapy , by Region USD Million (2017-2022)
  • Table 18. South America Diabetic Neuropathy, by Country USD Million (2017-2022)
  • Table 19. South America Diabetic Neuropathy, by Type USD Million (2017-2022)
  • Table 20. South America Diabetic Neuropathy, by Application USD Million (2017-2022)
  • Table 21. South America Diabetic Neuropathy, by Drug Type USD Million (2017-2022)
  • Table 22. South America Diabetic Neuropathy, by Therapy USD Million (2017-2022)
  • Table 23. Brazil Diabetic Neuropathy, by Type USD Million (2017-2022)
  • Table 24. Brazil Diabetic Neuropathy, by Application USD Million (2017-2022)
  • Table 25. Brazil Diabetic Neuropathy, by Drug Type USD Million (2017-2022)
  • Table 26. Brazil Diabetic Neuropathy, by Therapy USD Million (2017-2022)
  • Table 27. Argentina Diabetic Neuropathy, by Type USD Million (2017-2022)
  • Table 28. Argentina Diabetic Neuropathy, by Application USD Million (2017-2022)
  • Table 29. Argentina Diabetic Neuropathy, by Drug Type USD Million (2017-2022)
  • Table 30. Argentina Diabetic Neuropathy, by Therapy USD Million (2017-2022)
  • Table 31. Rest of South America Diabetic Neuropathy, by Type USD Million (2017-2022)
  • Table 32. Rest of South America Diabetic Neuropathy, by Application USD Million (2017-2022)
  • Table 33. Rest of South America Diabetic Neuropathy, by Drug Type USD Million (2017-2022)
  • Table 34. Rest of South America Diabetic Neuropathy, by Therapy USD Million (2017-2022)
  • Table 35. Asia Pacific Diabetic Neuropathy, by Country USD Million (2017-2022)
  • Table 36. Asia Pacific Diabetic Neuropathy, by Type USD Million (2017-2022)
  • Table 37. Asia Pacific Diabetic Neuropathy, by Application USD Million (2017-2022)
  • Table 38. Asia Pacific Diabetic Neuropathy, by Drug Type USD Million (2017-2022)
  • Table 39. Asia Pacific Diabetic Neuropathy, by Therapy USD Million (2017-2022)
  • Table 40. China Diabetic Neuropathy, by Type USD Million (2017-2022)
  • Table 41. China Diabetic Neuropathy, by Application USD Million (2017-2022)
  • Table 42. China Diabetic Neuropathy, by Drug Type USD Million (2017-2022)
  • Table 43. China Diabetic Neuropathy, by Therapy USD Million (2017-2022)
  • Table 44. Japan Diabetic Neuropathy, by Type USD Million (2017-2022)
  • Table 45. Japan Diabetic Neuropathy, by Application USD Million (2017-2022)
  • Table 46. Japan Diabetic Neuropathy, by Drug Type USD Million (2017-2022)
  • Table 47. Japan Diabetic Neuropathy, by Therapy USD Million (2017-2022)
  • Table 48. India Diabetic Neuropathy, by Type USD Million (2017-2022)
  • Table 49. India Diabetic Neuropathy, by Application USD Million (2017-2022)
  • Table 50. India Diabetic Neuropathy, by Drug Type USD Million (2017-2022)
  • Table 51. India Diabetic Neuropathy, by Therapy USD Million (2017-2022)
  • Table 52. South Korea Diabetic Neuropathy, by Type USD Million (2017-2022)
  • Table 53. South Korea Diabetic Neuropathy, by Application USD Million (2017-2022)
  • Table 54. South Korea Diabetic Neuropathy, by Drug Type USD Million (2017-2022)
  • Table 55. South Korea Diabetic Neuropathy, by Therapy USD Million (2017-2022)
  • Table 56. Taiwan Diabetic Neuropathy, by Type USD Million (2017-2022)
  • Table 57. Taiwan Diabetic Neuropathy, by Application USD Million (2017-2022)
  • Table 58. Taiwan Diabetic Neuropathy, by Drug Type USD Million (2017-2022)
  • Table 59. Taiwan Diabetic Neuropathy, by Therapy USD Million (2017-2022)
  • Table 60. Australia Diabetic Neuropathy, by Type USD Million (2017-2022)
  • Table 61. Australia Diabetic Neuropathy, by Application USD Million (2017-2022)
  • Table 62. Australia Diabetic Neuropathy, by Drug Type USD Million (2017-2022)
  • Table 63. Australia Diabetic Neuropathy, by Therapy USD Million (2017-2022)
  • Table 64. Rest of Asia-Pacific Diabetic Neuropathy, by Type USD Million (2017-2022)
  • Table 65. Rest of Asia-Pacific Diabetic Neuropathy, by Application USD Million (2017-2022)
  • Table 66. Rest of Asia-Pacific Diabetic Neuropathy, by Drug Type USD Million (2017-2022)
  • Table 67. Rest of Asia-Pacific Diabetic Neuropathy, by Therapy USD Million (2017-2022)
  • Table 68. Europe Diabetic Neuropathy, by Country USD Million (2017-2022)
  • Table 69. Europe Diabetic Neuropathy, by Type USD Million (2017-2022)
  • Table 70. Europe Diabetic Neuropathy, by Application USD Million (2017-2022)
  • Table 71. Europe Diabetic Neuropathy, by Drug Type USD Million (2017-2022)
  • Table 72. Europe Diabetic Neuropathy, by Therapy USD Million (2017-2022)
  • Table 73. Germany Diabetic Neuropathy, by Type USD Million (2017-2022)
  • Table 74. Germany Diabetic Neuropathy, by Application USD Million (2017-2022)
  • Table 75. Germany Diabetic Neuropathy, by Drug Type USD Million (2017-2022)
  • Table 76. Germany Diabetic Neuropathy, by Therapy USD Million (2017-2022)
  • Table 77. France Diabetic Neuropathy, by Type USD Million (2017-2022)
  • Table 78. France Diabetic Neuropathy, by Application USD Million (2017-2022)
  • Table 79. France Diabetic Neuropathy, by Drug Type USD Million (2017-2022)
  • Table 80. France Diabetic Neuropathy, by Therapy USD Million (2017-2022)
  • Table 81. Italy Diabetic Neuropathy, by Type USD Million (2017-2022)
  • Table 82. Italy Diabetic Neuropathy, by Application USD Million (2017-2022)
  • Table 83. Italy Diabetic Neuropathy, by Drug Type USD Million (2017-2022)
  • Table 84. Italy Diabetic Neuropathy, by Therapy USD Million (2017-2022)
  • Table 85. United Kingdom Diabetic Neuropathy, by Type USD Million (2017-2022)
  • Table 86. United Kingdom Diabetic Neuropathy, by Application USD Million (2017-2022)
  • Table 87. United Kingdom Diabetic Neuropathy, by Drug Type USD Million (2017-2022)
  • Table 88. United Kingdom Diabetic Neuropathy, by Therapy USD Million (2017-2022)
  • Table 89. Netherlands Diabetic Neuropathy, by Type USD Million (2017-2022)
  • Table 90. Netherlands Diabetic Neuropathy, by Application USD Million (2017-2022)
  • Table 91. Netherlands Diabetic Neuropathy, by Drug Type USD Million (2017-2022)
  • Table 92. Netherlands Diabetic Neuropathy, by Therapy USD Million (2017-2022)
  • Table 93. Rest of Europe Diabetic Neuropathy, by Type USD Million (2017-2022)
  • Table 94. Rest of Europe Diabetic Neuropathy, by Application USD Million (2017-2022)
  • Table 95. Rest of Europe Diabetic Neuropathy, by Drug Type USD Million (2017-2022)
  • Table 96. Rest of Europe Diabetic Neuropathy, by Therapy USD Million (2017-2022)
  • Table 97. MEA Diabetic Neuropathy, by Country USD Million (2017-2022)
  • Table 98. MEA Diabetic Neuropathy, by Type USD Million (2017-2022)
  • Table 99. MEA Diabetic Neuropathy, by Application USD Million (2017-2022)
  • Table 100. MEA Diabetic Neuropathy, by Drug Type USD Million (2017-2022)
  • Table 101. MEA Diabetic Neuropathy, by Therapy USD Million (2017-2022)
  • Table 102. Middle East Diabetic Neuropathy, by Type USD Million (2017-2022)
  • Table 103. Middle East Diabetic Neuropathy, by Application USD Million (2017-2022)
  • Table 104. Middle East Diabetic Neuropathy, by Drug Type USD Million (2017-2022)
  • Table 105. Middle East Diabetic Neuropathy, by Therapy USD Million (2017-2022)
  • Table 106. Africa Diabetic Neuropathy, by Type USD Million (2017-2022)
  • Table 107. Africa Diabetic Neuropathy, by Application USD Million (2017-2022)
  • Table 108. Africa Diabetic Neuropathy, by Drug Type USD Million (2017-2022)
  • Table 109. Africa Diabetic Neuropathy, by Therapy USD Million (2017-2022)
  • Table 110. North America Diabetic Neuropathy, by Country USD Million (2017-2022)
  • Table 111. North America Diabetic Neuropathy, by Type USD Million (2017-2022)
  • Table 112. North America Diabetic Neuropathy, by Application USD Million (2017-2022)
  • Table 113. North America Diabetic Neuropathy, by Drug Type USD Million (2017-2022)
  • Table 114. North America Diabetic Neuropathy, by Therapy USD Million (2017-2022)
  • Table 115. United States Diabetic Neuropathy, by Type USD Million (2017-2022)
  • Table 116. United States Diabetic Neuropathy, by Application USD Million (2017-2022)
  • Table 117. United States Diabetic Neuropathy, by Drug Type USD Million (2017-2022)
  • Table 118. United States Diabetic Neuropathy, by Therapy USD Million (2017-2022)
  • Table 119. Canada Diabetic Neuropathy, by Type USD Million (2017-2022)
  • Table 120. Canada Diabetic Neuropathy, by Application USD Million (2017-2022)
  • Table 121. Canada Diabetic Neuropathy, by Drug Type USD Million (2017-2022)
  • Table 122. Canada Diabetic Neuropathy, by Therapy USD Million (2017-2022)
  • Table 123. Mexico Diabetic Neuropathy, by Type USD Million (2017-2022)
  • Table 124. Mexico Diabetic Neuropathy, by Application USD Million (2017-2022)
  • Table 125. Mexico Diabetic Neuropathy, by Drug Type USD Million (2017-2022)
  • Table 126. Mexico Diabetic Neuropathy, by Therapy USD Million (2017-2022)
  • Table 127. Diabetic Neuropathy: by Type(USD/Units)
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Diabetic Neuropathy: by Type(USD Million)
  • Table 137. Diabetic Neuropathy Peripheral Neuropathy , by Region USD Million (2023-2028)
  • Table 138. Diabetic Neuropathy Autonomic Neuropathy , by Region USD Million (2023-2028)
  • Table 139. Diabetic Neuropathy Proximal Neuropathy , by Region USD Million (2023-2028)
  • Table 140. Diabetic Neuropathy Focal Neuropathy , by Region USD Million (2023-2028)
  • Table 141. Diabetic Neuropathy: by Application(USD Million)
  • Table 142. Diabetic Neuropathy Hospitals , by Region USD Million (2023-2028)
  • Table 143. Diabetic Neuropathy Clinics , by Region USD Million (2023-2028)
  • Table 144. Diabetic Neuropathy Retail Pharmacy , by Region USD Million (2023-2028)
  • Table 145. Diabetic Neuropathy Online Pharmacy , by Region USD Million (2023-2028)
  • Table 146. Diabetic Neuropathy: by Drug Type(USD Million)
  • Table 147. Diabetic Neuropathy Analgesic (Topical, Opoid, NSAIDs) , by Region USD Million (2023-2028)
  • Table 148. Diabetic Neuropathy Antidepressants (TCAs, SNRIs, SSRIs) , by Region USD Million (2023-2028)
  • Table 149. Diabetic Neuropathy Anticonvulsant Drugs (Gabapentin, Pregabalin, Topiramate) , by Region USD Million (2023-2028)
  • Table 150. Diabetic Neuropathy: by Therapy(USD Million)
  • Table 151. Diabetic Neuropathy Radiotherapy (Transcutaneous Electrical Nerve Stimulation (TENS)) , by Region USD Million (2023-2028)
  • Table 152. Diabetic Neuropathy Physiotherapy , by Region USD Million (2023-2028)
  • Table 153. South America Diabetic Neuropathy, by Country USD Million (2023-2028)
  • Table 154. South America Diabetic Neuropathy, by Type USD Million (2023-2028)
  • Table 155. South America Diabetic Neuropathy, by Application USD Million (2023-2028)
  • Table 156. South America Diabetic Neuropathy, by Drug Type USD Million (2023-2028)
  • Table 157. South America Diabetic Neuropathy, by Therapy USD Million (2023-2028)
  • Table 158. Brazil Diabetic Neuropathy, by Type USD Million (2023-2028)
  • Table 159. Brazil Diabetic Neuropathy, by Application USD Million (2023-2028)
  • Table 160. Brazil Diabetic Neuropathy, by Drug Type USD Million (2023-2028)
  • Table 161. Brazil Diabetic Neuropathy, by Therapy USD Million (2023-2028)
  • Table 162. Argentina Diabetic Neuropathy, by Type USD Million (2023-2028)
  • Table 163. Argentina Diabetic Neuropathy, by Application USD Million (2023-2028)
  • Table 164. Argentina Diabetic Neuropathy, by Drug Type USD Million (2023-2028)
  • Table 165. Argentina Diabetic Neuropathy, by Therapy USD Million (2023-2028)
  • Table 166. Rest of South America Diabetic Neuropathy, by Type USD Million (2023-2028)
  • Table 167. Rest of South America Diabetic Neuropathy, by Application USD Million (2023-2028)
  • Table 168. Rest of South America Diabetic Neuropathy, by Drug Type USD Million (2023-2028)
  • Table 169. Rest of South America Diabetic Neuropathy, by Therapy USD Million (2023-2028)
  • Table 170. Asia Pacific Diabetic Neuropathy, by Country USD Million (2023-2028)
  • Table 171. Asia Pacific Diabetic Neuropathy, by Type USD Million (2023-2028)
  • Table 172. Asia Pacific Diabetic Neuropathy, by Application USD Million (2023-2028)
  • Table 173. Asia Pacific Diabetic Neuropathy, by Drug Type USD Million (2023-2028)
  • Table 174. Asia Pacific Diabetic Neuropathy, by Therapy USD Million (2023-2028)
  • Table 175. China Diabetic Neuropathy, by Type USD Million (2023-2028)
  • Table 176. China Diabetic Neuropathy, by Application USD Million (2023-2028)
  • Table 177. China Diabetic Neuropathy, by Drug Type USD Million (2023-2028)
  • Table 178. China Diabetic Neuropathy, by Therapy USD Million (2023-2028)
  • Table 179. Japan Diabetic Neuropathy, by Type USD Million (2023-2028)
  • Table 180. Japan Diabetic Neuropathy, by Application USD Million (2023-2028)
  • Table 181. Japan Diabetic Neuropathy, by Drug Type USD Million (2023-2028)
  • Table 182. Japan Diabetic Neuropathy, by Therapy USD Million (2023-2028)
  • Table 183. India Diabetic Neuropathy, by Type USD Million (2023-2028)
  • Table 184. India Diabetic Neuropathy, by Application USD Million (2023-2028)
  • Table 185. India Diabetic Neuropathy, by Drug Type USD Million (2023-2028)
  • Table 186. India Diabetic Neuropathy, by Therapy USD Million (2023-2028)
  • Table 187. South Korea Diabetic Neuropathy, by Type USD Million (2023-2028)
  • Table 188. South Korea Diabetic Neuropathy, by Application USD Million (2023-2028)
  • Table 189. South Korea Diabetic Neuropathy, by Drug Type USD Million (2023-2028)
  • Table 190. South Korea Diabetic Neuropathy, by Therapy USD Million (2023-2028)
  • Table 191. Taiwan Diabetic Neuropathy, by Type USD Million (2023-2028)
  • Table 192. Taiwan Diabetic Neuropathy, by Application USD Million (2023-2028)
  • Table 193. Taiwan Diabetic Neuropathy, by Drug Type USD Million (2023-2028)
  • Table 194. Taiwan Diabetic Neuropathy, by Therapy USD Million (2023-2028)
  • Table 195. Australia Diabetic Neuropathy, by Type USD Million (2023-2028)
  • Table 196. Australia Diabetic Neuropathy, by Application USD Million (2023-2028)
  • Table 197. Australia Diabetic Neuropathy, by Drug Type USD Million (2023-2028)
  • Table 198. Australia Diabetic Neuropathy, by Therapy USD Million (2023-2028)
  • Table 199. Rest of Asia-Pacific Diabetic Neuropathy, by Type USD Million (2023-2028)
  • Table 200. Rest of Asia-Pacific Diabetic Neuropathy, by Application USD Million (2023-2028)
  • Table 201. Rest of Asia-Pacific Diabetic Neuropathy, by Drug Type USD Million (2023-2028)
  • Table 202. Rest of Asia-Pacific Diabetic Neuropathy, by Therapy USD Million (2023-2028)
  • Table 203. Europe Diabetic Neuropathy, by Country USD Million (2023-2028)
  • Table 204. Europe Diabetic Neuropathy, by Type USD Million (2023-2028)
  • Table 205. Europe Diabetic Neuropathy, by Application USD Million (2023-2028)
  • Table 206. Europe Diabetic Neuropathy, by Drug Type USD Million (2023-2028)
  • Table 207. Europe Diabetic Neuropathy, by Therapy USD Million (2023-2028)
  • Table 208. Germany Diabetic Neuropathy, by Type USD Million (2023-2028)
  • Table 209. Germany Diabetic Neuropathy, by Application USD Million (2023-2028)
  • Table 210. Germany Diabetic Neuropathy, by Drug Type USD Million (2023-2028)
  • Table 211. Germany Diabetic Neuropathy, by Therapy USD Million (2023-2028)
  • Table 212. France Diabetic Neuropathy, by Type USD Million (2023-2028)
  • Table 213. France Diabetic Neuropathy, by Application USD Million (2023-2028)
  • Table 214. France Diabetic Neuropathy, by Drug Type USD Million (2023-2028)
  • Table 215. France Diabetic Neuropathy, by Therapy USD Million (2023-2028)
  • Table 216. Italy Diabetic Neuropathy, by Type USD Million (2023-2028)
  • Table 217. Italy Diabetic Neuropathy, by Application USD Million (2023-2028)
  • Table 218. Italy Diabetic Neuropathy, by Drug Type USD Million (2023-2028)
  • Table 219. Italy Diabetic Neuropathy, by Therapy USD Million (2023-2028)
  • Table 220. United Kingdom Diabetic Neuropathy, by Type USD Million (2023-2028)
  • Table 221. United Kingdom Diabetic Neuropathy, by Application USD Million (2023-2028)
  • Table 222. United Kingdom Diabetic Neuropathy, by Drug Type USD Million (2023-2028)
  • Table 223. United Kingdom Diabetic Neuropathy, by Therapy USD Million (2023-2028)
  • Table 224. Netherlands Diabetic Neuropathy, by Type USD Million (2023-2028)
  • Table 225. Netherlands Diabetic Neuropathy, by Application USD Million (2023-2028)
  • Table 226. Netherlands Diabetic Neuropathy, by Drug Type USD Million (2023-2028)
  • Table 227. Netherlands Diabetic Neuropathy, by Therapy USD Million (2023-2028)
  • Table 228. Rest of Europe Diabetic Neuropathy, by Type USD Million (2023-2028)
  • Table 229. Rest of Europe Diabetic Neuropathy, by Application USD Million (2023-2028)
  • Table 230. Rest of Europe Diabetic Neuropathy, by Drug Type USD Million (2023-2028)
  • Table 231. Rest of Europe Diabetic Neuropathy, by Therapy USD Million (2023-2028)
  • Table 232. MEA Diabetic Neuropathy, by Country USD Million (2023-2028)
  • Table 233. MEA Diabetic Neuropathy, by Type USD Million (2023-2028)
  • Table 234. MEA Diabetic Neuropathy, by Application USD Million (2023-2028)
  • Table 235. MEA Diabetic Neuropathy, by Drug Type USD Million (2023-2028)
  • Table 236. MEA Diabetic Neuropathy, by Therapy USD Million (2023-2028)
  • Table 237. Middle East Diabetic Neuropathy, by Type USD Million (2023-2028)
  • Table 238. Middle East Diabetic Neuropathy, by Application USD Million (2023-2028)
  • Table 239. Middle East Diabetic Neuropathy, by Drug Type USD Million (2023-2028)
  • Table 240. Middle East Diabetic Neuropathy, by Therapy USD Million (2023-2028)
  • Table 241. Africa Diabetic Neuropathy, by Type USD Million (2023-2028)
  • Table 242. Africa Diabetic Neuropathy, by Application USD Million (2023-2028)
  • Table 243. Africa Diabetic Neuropathy, by Drug Type USD Million (2023-2028)
  • Table 244. Africa Diabetic Neuropathy, by Therapy USD Million (2023-2028)
  • Table 245. North America Diabetic Neuropathy, by Country USD Million (2023-2028)
  • Table 246. North America Diabetic Neuropathy, by Type USD Million (2023-2028)
  • Table 247. North America Diabetic Neuropathy, by Application USD Million (2023-2028)
  • Table 248. North America Diabetic Neuropathy, by Drug Type USD Million (2023-2028)
  • Table 249. North America Diabetic Neuropathy, by Therapy USD Million (2023-2028)
  • Table 250. United States Diabetic Neuropathy, by Type USD Million (2023-2028)
  • Table 251. United States Diabetic Neuropathy, by Application USD Million (2023-2028)
  • Table 252. United States Diabetic Neuropathy, by Drug Type USD Million (2023-2028)
  • Table 253. United States Diabetic Neuropathy, by Therapy USD Million (2023-2028)
  • Table 254. Canada Diabetic Neuropathy, by Type USD Million (2023-2028)
  • Table 255. Canada Diabetic Neuropathy, by Application USD Million (2023-2028)
  • Table 256. Canada Diabetic Neuropathy, by Drug Type USD Million (2023-2028)
  • Table 257. Canada Diabetic Neuropathy, by Therapy USD Million (2023-2028)
  • Table 258. Mexico Diabetic Neuropathy, by Type USD Million (2023-2028)
  • Table 259. Mexico Diabetic Neuropathy, by Application USD Million (2023-2028)
  • Table 260. Mexico Diabetic Neuropathy, by Drug Type USD Million (2023-2028)
  • Table 261. Mexico Diabetic Neuropathy, by Therapy USD Million (2023-2028)
  • Table 262. Diabetic Neuropathy: by Type(USD/Units)
  • Table 263. Research Programs/Design for This Report
  • Table 264. Key Data Information from Secondary Sources
  • Table 265. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Diabetic Neuropathy: by Type USD Million (2017-2022)
  • Figure 5. Global Diabetic Neuropathy: by Application USD Million (2017-2022)
  • Figure 6. Global Diabetic Neuropathy: by Drug Type USD Million (2017-2022)
  • Figure 7. Global Diabetic Neuropathy: by Therapy USD Million (2017-2022)
  • Figure 8. South America Diabetic Neuropathy Share (%), by Country
  • Figure 9. Asia Pacific Diabetic Neuropathy Share (%), by Country
  • Figure 10. Europe Diabetic Neuropathy Share (%), by Country
  • Figure 11. MEA Diabetic Neuropathy Share (%), by Country
  • Figure 12. North America Diabetic Neuropathy Share (%), by Country
  • Figure 13. Global Diabetic Neuropathy: by Type USD/Units (2017-2022)
  • Figure 14. Global Diabetic Neuropathy share by Players 2022 (%)
  • Figure 15. Global Diabetic Neuropathy share by Players (Top 3) 2022(%)
  • Figure 16. Global Diabetic Neuropathy share by Players (Top 5) 2022(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Pfizer Inc. (United States) Revenue: by Geography 2022
  • Figure 20. Janssen Pharmaceuticals, Inc. (Belgium) Revenue, Net Income and Gross profit
  • Figure 21. Janssen Pharmaceuticals, Inc. (Belgium) Revenue: by Geography 2022
  • Figure 22. Eli Lilly and Company (India) Revenue, Net Income and Gross profit
  • Figure 23. Eli Lilly and Company (India) Revenue: by Geography 2022
  • Figure 24. Teva Pharmaceutical Industries (United States) Revenue, Net Income and Gross profit
  • Figure 25. Teva Pharmaceutical Industries (United States) Revenue: by Geography 2022
  • Figure 26. Cephalon, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Cephalon, Inc. (United States) Revenue: by Geography 2022
  • Figure 28. MEDA Pharma GmbH & Co. KG (Germany) Revenue, Net Income and Gross profit
  • Figure 29. MEDA Pharma GmbH & Co. KG (Germany) Revenue: by Geography 2022
  • Figure 30. GlaxoSmithKline plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. GlaxoSmithKline plc. (United Kingdom) Revenue: by Geography 2022
  • Figure 32. NeuroMetrix, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 33. NeuroMetrix, Inc (United States) Revenue: by Geography 2022
  • Figure 34. Global Diabetic Neuropathy: by Type USD Million (2023-2028)
  • Figure 35. Global Diabetic Neuropathy: by Application USD Million (2023-2028)
  • Figure 36. Global Diabetic Neuropathy: by Drug Type USD Million (2023-2028)
  • Figure 37. Global Diabetic Neuropathy: by Therapy USD Million (2023-2028)
  • Figure 38. South America Diabetic Neuropathy Share (%), by Country
  • Figure 39. Asia Pacific Diabetic Neuropathy Share (%), by Country
  • Figure 40. Europe Diabetic Neuropathy Share (%), by Country
  • Figure 41. MEA Diabetic Neuropathy Share (%), by Country
  • Figure 42. North America Diabetic Neuropathy Share (%), by Country
  • Figure 43. Global Diabetic Neuropathy: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Pfizer Inc. (United States)
  • Janssen Pharmaceuticals, Inc. (Belgium)
  • Eli Lilly and Company (India)
  • Teva Pharmaceutical Industries (United States)
  • Cephalon, Inc. (United States)
  • MEDA Pharma GmbH & Co. KG (Germany)
  • GlaxoSmithKline plc. (United Kingdom)
  • NeuroMetrix, Inc (United States)
Additional players considered in the study are as follows:
Mitsubishi Tanabe Pharma Corporation (Japan) , Allergan PLC (Ireland) , Regenancy Pharmaceuticals (United States) , Daiichi Sankyo Company, Limited (Japan)
Select User Access Type

Key Highlights of Report


Jan 2024 249 Pages 92 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Diabetic Neuropathy Quantitative research analysis
Global Diabetic Neuropathy Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Diabetic Neuropathy market are Pfizer Inc. (United States), Janssen Pharmaceuticals, Inc. (Belgium), Eli Lilly and Company (India), Teva Pharmaceutical Industries (United States), Cephalon, Inc. (United States), MEDA Pharma GmbH & Co. KG (Germany), GlaxoSmithKline plc. (United Kingdom) and NeuroMetrix, Inc (United States), to name a few.
North America is dominating the Diabetic Neuropathy Market.
"The strict regulatory scenario for drug approval in developed countries has been a challenge for the diabetic neuropathy market." is seen as one of the major challenges by many Industry Players of Diabetic Neuropathy Market
The Diabetic Neuropathy market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Diabetic Neuropathy market is expected to see a steady growth rate during projected year 2022 to 2028.

Know More About Global Diabetic Neuropathy Report?

Have a Query? Click Here

Other Related Reports

Donepezil Comprehensive Study by Type (5mg, 10mg, 23mg), Application (Hospitals, Clinics, Drugstore), Distribution Channel (Online, Offline) Players and Region - Global Market Outlook to 2027
$ 3500
Leukemia Therapeutics Comprehensive Study by Type (Chemotherapy, Biological Therapy, Radiation therapy, Targeted therapy), Application (Hospital, Clinic), Mode of Administration (Oral, Injectable), M...
$ 3750
Age Related Macular Degeneration Comprehensive Study by Type (Wet AMD, Dry AMD), Drugs (Lucentis, Eylea, Avastin, Others), Route of Administration (Intravenous, Intravitreal) Players and Region - Glo...
$ 3500
Diabetic Nephropathy Comprehensive Study by Application (Hospitals, Cancer Research Institutes, Diagnostic Labs), Treatment (Medication, Kidney Dialysis, Kidney Transplant), Stages (Microalbuminuria ...
$ 3750
Negative Pressure Wound Therapy Comprehensive Study by Type (Standalone NPWT Devices, Single use Disposable NPWT Devices, Portable NPWT Devices, NPWT Accessories (Canister)), Application (Hospital, C...
$ 3350
Chitosan Gel Comprehensive Study by Type (Industrial Grade, Pharmaceutical Grade, Others), Application (Surgical, Gynecological Diseases, Hemorrhoid Disease, Others), Distribution Channel (Hospital P...
$ 3450